Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications.

Sci Rep 2015 Apr 27;5:9526. Epub 2015 Apr 27.

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.

The remarkable clinical success of Fc-fusion proteins has driven intense investigation for even more potent replacements. Using quality-by-design (QbD) approaches, we generated hexameric-Fc (hexa-Fc), a ~20 nm oligomeric Fc-based scaffold that we here show binds low-affinity inhibitory receptors (FcRL5, FcγRIIb, and DC-SIGN) with high avidity and specificity, whilst eliminating significant clinical limitations of monomeric Fc-fusions for vaccine and/or cancer therapies, in particular their poor ability to activate complement. Mass spectroscopy of hexa-Fc reveals high-mannose, low-sialic acid content, suggesting that interactions with these receptors are influenced by the mannose-containing Fc. Molecular dynamics (MD) simulations provides insight into the mechanisms of hexa-Fc interaction with these receptors and reveals an unexpected orientation of high-mannose glycans on the human Fc that provides greater accessibility to potential binding partners. Finally, we show that this biosynthetic nanoparticle can be engineered to enhance interactions with the human neonatal Fc receptor (FcRn) without loss of the oligomeric structure, a crucial modification for these molecules in therapy and/or vaccine strategies where a long plasma half-life is critical.

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep09526DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224519PMC
April 2015
26 Reads

Publication Analysis

Top Keywords

suggesting interactions
4
interactions receptors
4
receptors influenced
4
content suggesting
4
acid content
4
high-mannose low-sialic
4
low-sialic acid
4
influenced mannose-containing
4
mannose-containing molecular
4
mechanisms hexa-fc
4
hexa-fc interaction
4
interaction receptors
4
insight mechanisms
4
simulations insight
4
molecular dynamics
4
dynamics simulations
4
reveals high-mannose
4
hexa-fc reveals
4
limitations monomeric
4
monomeric fc-fusions
4

References

(Supplied by CrossRef)

DM Czajkowsky et al.
EMBO. Mol. Med. 2012

RS Aggarwal et al.
Nat. Biotech. 2014

L Ye et al.
Nat. Biotech. 2011

A Jain et al.
Arthritis Res. Thera. 2012

M Daeron et al.
J. Clin. Invest. 1995

TJ Wilson et al.
J. Immunol. 2012

K Su et al.
J. Immunol. 2007

TB Geijtenbeek et al.
Cell 2000

P Sondermann et al.
Proc. Natl. Acad. Sci. USA. 2013

X Yu et al.
J. Mol. Biol. 2013

RM Anthony et al.
Nature 2011

Similar Publications